2012 Book Halogenatedhetero
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Lewis Acid Mediated Reactions of Olefins with Carbonyls
Lewis Acid Mediated Reactions of Olefins with Carbonyls Submitted by Stephen Flower For the Degree of PhD Of the University of Bath 2002 COPYRIGHT Attention is drawn to the fact that copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without the prior written consent of the author. This thesis may be made available for consultation within the University Library and may be photocopied or lent to other libraries for the purposes of consultation. …………………………..(signed) …………………………..(date) Abstract This thesis is divided into 5 chapters. The first chapter reviews the literature of Carbonyl-ene and Prins reactions. Recent advances in these areas and their application to natural product synthesis and other targeted syntheses are discussed. The second chapter discusses the concept of desymmetrisation using selected examples, including desymmetrising Carbonyl-ene reactions. Chapter Three introduces and discusses the work undertaken in studying the desymmetrising intramolecular carbonyl-ene of a meso-dialdehyde. Chapter Four details the concept of pyruvate-Prins cyclisation giving examples of its potential use. The chapter also gives examples of the use of rigid stereodefined scaffolds and their application. The chapter describes the reactivity of substituted pyruvate esters with cyclic enol ethers, and the elaboration of the cyclised products. The fifth chapter provides experimental details of the procedures reported. i Acknowledgements Many thanks to Dr Mike Willis for all his help and guidance and boundless enthusiasm over the years; and for a detailed investigation of the local pubs. -
BI(III) Initiated Cyclization Reactions and Iodonium Fragmentation Kinetics
W&M ScholarWorks Dissertations, Theses, and Masters Projects Theses, Dissertations, & Master Projects 2005 BI(III) Initiated Cyclization Reactions and Iodonium Fragmentation Kinetics Yajing Lian College of William & Mary - Arts & Sciences Follow this and additional works at: https://scholarworks.wm.edu/etd Part of the Inorganic Chemistry Commons Recommended Citation Lian, Yajing, "BI(III) Initiated Cyclization Reactions and Iodonium Fragmentation Kinetics" (2005). Dissertations, Theses, and Masters Projects. Paper 1539626842. https://dx.doi.org/doi:10.21220/s2-zj7g-fp23 This Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Dissertations, Theses, and Masters Projects by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. BI(III) INITIATED CYCLIZATION REACTIONS AND IODONIUM FRAGMENTATION KINETICS A Thesis Presented to The Faculty of the Department of Chemistry The College of William and Mary in Virginia In Partial Fulfillment Of the Requirements for the Degree of Master of Science by Yajing Lian 2005 APPROVAL SHEET This thesis is submitted in partial fulfillment of The requirements for the degree of Master of Science A Yajing Lian Approved by the Committee, December 20, 2005 Robert J. Hinkle, Chair Christopher Jl A] Robert D. Pike TABLE OF CONTENTS Page Acknowledgements VI List of Tables Vll List of Schemes V lll List of Figures IX Abstract XI Introduction Chapter I Secondary -
Accessing Light-Sensitive Polycyclic Aromatics Through an Alkynyl-Prins Cyclization
W&M ScholarWorks Undergraduate Honors Theses Theses, Dissertations, & Master Projects 4-2018 Accessing Light-Sensitive Polycyclic Aromatics through an Alkynyl-Prins Cyclization Daniel John Speer Follow this and additional works at: https://scholarworks.wm.edu/honorstheses Part of the Chemistry Commons Recommended Citation Speer, Daniel John, "Accessing Light-Sensitive Polycyclic Aromatics through an Alkynyl-Prins Cyclization" (2018). Undergraduate Honors Theses. Paper 1244. https://scholarworks.wm.edu/honorstheses/1244 This Honors Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. Accessing Light-Sensitive Polycyclic Aromatics through an Alkynyl-Prins Cyclization A thesis submitted in partial fulfillment of the requirement for the degree of Bachelor of Science with Honors in the Department of Chemistry from the College of William and Mary Accepted for Dr. Jonathan Scheerer Dr. Christopher Abelt Dr. Anne Rasmussen Directed by Dr. Robert J. Hinkle By Daniel John Speer April 26, 2018 Table of Contents Acknowledgements 3 Abstract 4 List of Figures 5 Introduction 6 Prins Chemistry and the alkynyl-Prins Cyclization 6 Photochromic Compounds 9 Cannabinoids 12 Results and Discussion 16 Development of Synthetic Procedure 16 Synthesis of Starting Material 17 Proposed Mechanism for the Cyclization 21 Synthesis and NMR Properties of Chromene Products 24 X-ray Crystallographic Analysis 27 UV/Visible Spectrophotometric Analysis 30 Conclusion 33 Experimental Methods 34 Materials and Methods 34 Synthetic Procedures 35 References 43 Supporting Information 46 Mass Spectrum of 11 46 X-ray Crystal Data and Structure Refinement for 11 47 2 Acknowledgements I would like to thank everyone involved in this process. -
Synthetic Strategies for the Lepadiformines and Cylindricine C Via Tandem Schmidt Reactions
Synthetic Strategies for the Lepadiformines and Cylindricine C via Tandem Schmidt Reactions By Angelica M. Meyer Submitted to the graduate degree program in the Medicinal Chemistry and the Graduate Faculty of The University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. ________________________________ Chairperson: Jeffrey Aubé ________________________________ Dr. Thomas E. Prisinzano ________________________________ Dr. Ryan A. Altman ________________________________ Dean Kenneth L. Audus ________________________________ Dr. Paul R. Hanson Date Defended: December 5, 2011 The Dissertation Committee for Angelica M. Meyer certifies that this is the approved version of the following thesis: Synthetic Strategies for the Lepadiformines and Cylindricine C via Tandem Schmidt Reactions ________________________________ Chairperson Jeffrey Aubé Date approved: December 5, 2011 ii Abstract Marine flora and fauna have provided numerous alluring natural products, some of which contribute to treating diseases. The genus Clavelina is the source of a variety of tricyclic alkaloids, including the lepadiformine and cylindricine families. Novel approaches to synthesizing these molecules are sought after to increase their accessibility and for analogue development. In this dissertation, reaction sequences involving an intramolecular Schmidt transformation, which can quickly build up the molecular architecture associated with these targets is described. In one approach, the Lewis acid promoted intramolecular Schmidt reaction is combined in series with a Prins reaction to afford an interesting tricyclic lactam. This methodology culminates in a formal synthesis of lepadiformine A and a total synthesis of lepadiformine C. In another project, a tandem Diels–Alder/Schmidt reaction is utilized to prepare a similar tricyclic lactam. This process is applied toward an asymmetric total synthesis of (–)-cylindricine C. -
(KPIC) PPO and Out-Of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier
Kaiser Permanente Insurance Company (KPIC) PPO and Out-of- Area Indemnity (OOA) Drug Formulary with Specialty Drug Tier This Drug Formulary was updated: September 1, 2021 NOTE: This drug formulary is updated often and is subject to change. Upon revision, all previous versions of the drug formulary are no longer in effect. This document contains information regarding the drugs that are covered when you participate in the California Nongrandfathered PPO and Out-of- Area Indemnity (OOA) Health Insurance Plans with specialty drug tier offered by Kaiser Permanente Insurance Company (KPIC) and fill your prescription at a MedImpact network pharmacy. Access to the most current version of the Formulary can be obtained by visiting kp.org/kpic-ca-rx-ppo-ngf. For help understanding your KPIC insurance plan benefits, including cost sharing for drugs under the prescription drug benefit and under the medical benefit, please call 1-800-788-0710 or 711 (TTY) Monday through Friday, 7a.m. to 7p.m. For help with this Formulary, including the processes for submitting an exception request and requesting prior authorization and step therapy exceptions, please call MedImpact 24 hours a day, 7 days a week, at 1-800-788-2949 or 711 (TTY). For cost sharing information for the outpatient prescription drug benefits in your specific plan, please visit: kp.org/kpic-ca-rx-ppo-ngf. For help in your preferred language, please see the Kaiser Permanente Insurance Company Notice of Language Assistance in this document. KPIC PPO NGF Table of Contents Informational Section................................................................................................................................2 -
Development of Metal-Catalyzed Reactions of Allenes with Imines and the Investigation of Brθnsted Acid Catalyzed Ene Reactions
DEVELOPMENT OF METAL-CATALYZED REACTIONS OF ALLENES WITH IMINES AND THE INVESTIGATION OF BRΘNSTED ACID CATALYZED ENE REACTIONS BY LINDSEY O. DAVIS A Dissertation Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL OF ARTS AND SCIENCES in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY in the Department of Chemistry December 2009 Winston-Salem, North Carolina Approved By: Paul B. Jones, Ph.D., Advisor ____________________________ Examining Committee: Christa L. Colyer, Ph.D., chair ____________________________ S. Bruce King, Ph. D. _______________________________ Dilip K. Kondepudi, Ph.D. _______________________________ Suzanne L. Tobey, Ph.D. _______________________________ ACKNOWLEDGMENTS I must first acknowledge my family for their support throughout my education. My mother has always encouraged me to ask questions and seek answers, which has guided my inquisitive nature as a scientist. My grandparents have taught me the importance of character and my father taught me the value in hard work. I’d also like to thank my husband for moving away from Georgia, a sacrifice I greatly appreciate. Also, his cheerful disposition helped me stay relatively positive, especially when I had bad research days. My friends also played a very important role in keeping me positive during my time at Wake. Particularly my roommates put up with me more than most. I’d like to thank Lauren Eiter for her sense of humor, Tara Weaver for her taste in books and movies, and Jenna DuMond, for her encouragement and loyalty. Also I’ve made lifetime friends with Meredith and Kavita, and even though they left me at Wake, they were always willing to offer their support. -
Traditional Open Drug List
Traditional Open Drug List Drug list — Four Tier Drug Plan Your prescription benefit comes with a drug list, which is also called a formulary. This list is made up of brand-name and generic prescription drugs approved by the U.S. Food & Drug Administration (FDA). Here are a few things to remember about the list: o You and your doctor can use it as a guide to choose drugs that are best for you. Drugs that aren’t on this list may not be covered by your plan and may cost you more out of pocket. o Your coverage has limitations and exclusions, which means there are certain rules about what's covered by your plan and what isn't. To find out more, view your Certificate/Evidence of Coverage or your Summary Plan Description by logging in at anthem.com and go to My Plan ->Benefits-> Plan Documents. o To help you see how the drug list works with your drug benefit, we've included some frequently asked questions (FAQ) about how the list is set up and what to do if a drug you take isn't on it. o This booklet is updated on a quarterly basis. To view the most up-to-date list of drugs for your plan - including drugs that have been added, generic drugs and more - log in at anthem.com and choose Prescription Benefits. If you have questions about your pharmacy benefits, we're here to help. Just call us at the Pharmacy Member Services number on your ID card. 05374MUMENABS Traditional Open Drug List What is a drug list? The drug list, also called a formulary, is a list of prescription medicines your plan covers. -
Download (4MB)
https://theses.gla.ac.uk/ Theses Digitisation: https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ This is a digitised version of the original print thesis. Copyright and moral rights for this work are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Enlighten: Theses https://theses.gla.ac.uk/ [email protected] SYNTHETIC AND BIOSYNTHETIC STUDIES ON SULPHUR-CONTAINING HETEROCYCLES A Thesis presented in part fulfilment of the requirement for the Degree of Doctor of Philosophy by Robert Andrew Lewis Department of Chemistry University of Glasgow September 1989 © ROBERT LEWIS 1989 ProQuest Number: 11003345 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 11003345 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. -
Identification, Isolation, Synthesis and Characterization of Impurities of Quetiapine Fumarate
ORIGINAL ARTICLES Aurobindo Pharma Ltd. Research Centre1, Bachupally, J. N. T. University2, Kukatpally, Hyderabad, India Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate Ch. Bharathi1, K. J. Prabahar1, Ch. S. Prasad1, M. Srinivasa Rao1, G. N. Trinadhachary1, V. K. Handa1, R. Dandala1, A. Naidu2 Received May 28, 2007, accepted June 18, 2007 Ramesh Dandala, Senior Vice-President, A. P. L. Research centre, 313, Bachupally, Hyderabad 500072, India [email protected] Pharmazie 63: 14–19 (2008) doi: 10.1691/ph.2008.7174 In the process for the preparation of quetiapine fumarate (1), six unknown impurities and one known impurity (intermediate) were identified ranging from 0.05–0.15% by reverse-phase HPLC. These impu- rities were isolated from crude samples using reverse-phase preparative HPLC. Based on the spectral data, the impurities were characterized as 2-[4-dibenzo[b,f ][1,4]thiazepine-11-yl-1-piperazinyl]1-2-etha- nol (impurity I, desethanol quetiapine), 11-[(N-formyl)-1-piperazinyl]-dibenzo[b,f ][1,4]thiazepine (impur- ity II, N-formyl piperazinyl thiazepine), 2-(2-hydroxy ethoxy)ethyl-2-[2-[4-dibenzo[b,f ][1,4]thiazepine-11- piperazinyl-1-carboxylate (impurity III, quetiapine carboxylate), 11-[4-ethyl-1-piperazinyl]dibenzo [b,f ][1,4] thiazepine (impurity IV, ethylpiperazinyl thiazepine), 2-[2-(4-dibenzo[b,f ][1,4]thiazepin-11-yl-1-piperazi- nyl)ethoxy]1-ethyl ethanol [impurity V, ethyl quetiapine), 1,4-bis[dibenzo[b,f ][1,4]thiazepine-11-yl] piper- azine [impurity VI, bis(dibenzo)piperazine]. The known impurity was an intermediate, 11-piperazinyl- dibenzo [b,f ][1,4]thiazepine (piperazinyl thiazepine). -
Anthem Blue Cross Prescription Formulary List
National Drug List Drug list — Three Tier Drug Plan Your prescription benefit comes with a drug list, which is also called a formulary. This list is made up of brand-name and generic prescription drugs approved by the U.S. Food & Drug Administration (FDA). We’re here to help. If you are a current Anthem member with questions about your pharmacy benefits, we're here to help. Just call us at the Member Services number on your ID card. The plan names to which this formulary applies are shown below. Solution PPO 1500/15/20 $5/$15/$50/$65/30% to $250 after deductible Solution PPO 2000/20/20 $5/$20/$30/$50/30% to $250 Solution PPO 2500/25/20 $5/$20/$40/$60/30% to $250 Solution PPO 3500/30/30 $5/$20/$40/$60/30% to $250 Rx ded $150 Solution PPO 4500/30/30 $5/$20/$40/$75/30% to $250 Solution PPO 5500/30/30 $5/$20/$40/$75/30% to $250 Rx ded $250 $5/$15/$25/$45/30% to $250 $5/$20/$50/$65/30% to $250 Rx ded $500 $5/$15/$30/$50/30% to $250 $5/$20/$50/$70/30% to $250 $5/$15/$40/$60/30% to $250 $5/$20/$50/$70/30% to $250 after deductible Here are a few things to remember: o You can view and search our current drug lists when you visit anthem.com/ca/pharmacyinformation. Please note: The formulary is subject to change and all previous versions of the formulary are no longer in effect. -
Central Nervous System 5 Objectives
B978-0-7234-3630-0.00005-4, 00005 Central nervous system 5 Objectives After reading this chapter, you will: ● Understand the functions of the central nervous system and the diseases that can occur ● Know the drug classes used to treat these conditions, their mechanisms of action and adverse effects. Parkinson’s disease is progressive, with continued BASIC CONCEPTS loss of dopaminergic neurons in the substantia nigra correlating with worsening of clinical symptoms. The The central nervous system consists of the brain and the possibility of a neurotoxic cause has been strengthe- spinal cord, which are continuous with one another. ned by the finding that 1-methyl-4-phenyl-1,2,3, The brain is composed of the cerebrum (which consists 6-tetrahydropyridine (MPTP), a chemical contaminant of the frontal, temporal, parietal and occipital lobes), of heroin, causes irreversible damage to the nigrostriatal the diencephalon (which includes the thalamus and dopaminergic pathway. Thus, this damage can lead hypothalamus), the brainstem (which consists of the mid- to the development of symptoms similar to those of brain, pons and medulla oblongata) and the cerebellum. idiopathic Parkinson’s disease. Drugs that block The brain functions to interpret sensory information dopamine receptors can also induce parkinsonism. obtained about the internal and external environments Neuroleptic drugs (p. 000) used in the treatment of TS1 and send messages to effector organs in response to a schizophrenia can produce parkinsonian symptoms as situation. Different parts of the brain are associated an adverse effect. Rare causes of parkinsonism are cere- with specific functions (Fig. 5.1). However, the brain is a bral ischaemia (progressive atherosclerosis or stroke), complex organ and is not yet completely understood. -
||||||||IHIII US005 130345A United States Patent (19) 11) Patent Number: 5,130,345 Li Et Al
||||||||IHIII US005 130345A United States Patent (19) 11) Patent Number: 5,130,345 Li et al. 45) Date of Patent: Jul. 14, 1992 (54) METHOD OF PREPARING FOAM USINGA 4,529,744 7/1985 Wood .................................. 521/1.31 PARTIALLY FLUORINATED ALKANE 4,624,970 1 1/1986 Dwyer et al. ....................... 521/13 HAVING ATERTARY STRUCTURE ASA OTHER PUBLICATIONS BLOWENGAGENT "The Perfluoro-ta-butyl Anion in the Synthesis of 75) Inventors: Chien C. Li, East Aurora, NY; Organofluorine Compounds"-Dyatkin et al. pard Sukornick, Cooper City, "How to Fix the CFC Mix', Chemicalweek/Oct. 18, 1989. 73) Assignee: AlliedSignal Inc. Morris Township, Pina Examiner-John Kight, III Morris County, N.J. Assistant Examiner-John M. Cooney, Jr. (21) Appl. No.: 546,173 Attorney, Agent, or Firm-Melanie L. Brown; Jay P. (22 Filed: Jun. 29, 1990 Friedenson CT 51 int.C.' ........................ co8J 9/14; cosGC08G 18/00,18/06 A method for ABSTRApreparing polyurethane and 52 U.S.C. ...................................... 521/131; 521/98; polyisocyanurate foams which comprises reacting and 521/155; 52 1/163.521/170 foaming a mixture of ingredients which will react to (58) Field of Search ................. 521/131,98, 155, 163, form the polyurethane or polyisocyanurate foams in the 52/170 presence of a blowing agent comprising a partially fluo 5 C rinated alkane having four or five carbon atoms and a (56) References Cited tertiary structure. The method is advantageous because U.S. PATENT DOCUMENTS partially fluorinated alkanes having a tertiary structure 3,183,92 5/1965 Bauer .................................. sy have zero ozone depletion potentials, are nonflamma 4,076,644 2/1978 Burnt et al.